• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Physician Health in the Times of COVID-19.

作者信息

Bavdekar S B, Chandrasekaran A, Govindarajan R P, Malik S, Bajaj S, Javeri Y, Niranjan V

机构信息

Chief Academics, Department of Pediatrics, Surya Hospital, Mumbai, Maharashtra.

Director, Clinical Development, RxMD, Chennai, Tamil Nadu.

出版信息

J Assoc Physicians India. 2020 Dec;68(12):21-27.

PMID:33247638
Abstract

BACKGROUND AND OBJECTIVES

A virtual registry study evaluating real world evidence on physicians' use of prophylactic regimens for protection against SARS-CoV-2. This paper summarizes the interim results.

METHODS

Asymptomatic physicians at risk of acquiring SARS-CoV-2 responded to online questions at baseline and 7 weeks post-baseline. Baseline data included demographics, prophylaxis regimen (including "no prophylaxis") and start date. Participants who provided complete week-7 data (information on type of health facility [COVID/Non-COVID], number of presumed/confirmed cases exposed to, PPE use, SARS-CoV-2 testing and symptoms, regimen adherence and intercurrent illness) comprised the Completer population. Limited data (regimen adherence, SARS-CoV-2 testing) was collected for participants who failed to provide complete week7 data. Those providing limited/complete information comprised the Evaluable population.

RESULTS

Of 369 enrolled participants, 182 (mean age 42±11.05 years) comprised the Evaluable population. They showed a male preponderance (67.6%). Practitioners from Maharashtra (59.9%) and specialties of Pediatrics, Internal Medicine, Anesthesiology and Critical Care (63.2%) accounted for the majority. ICMR's HCQ prophylaxis regimen was initiated by 125 (68.7%) participants with 31 (17%) initiating 'No prophylaxis'. The highest adherence was for the ICMRregimen (87.2%). In the Completer population comprising 150 participants, 87 were exposed to presumed (81) and/or confirmed cases (60). Most exposures to confirmed cases (49, 81.7%) were high-risk. PPE use was generally high (75-100%). Most participants (94.7%) did not report an AE. The proportions with an AE was similar with ICMR regimen (5.9%) and no prophylaxis (6.5%).

INTERPRETATION AND CONCLUSIONS

Physicians in India preferred ICMR's HCQ regimen. The regimen appears to be safe and associated with a high level of adherence.

摘要

相似文献

1
Physician Health in the Times of COVID-19.
J Assoc Physicians India. 2020 Dec;68(12):21-27.
2
Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.羟氯喹用于接触新冠病毒疾病(COVID-19)后成年人暴露者预防严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染的暴露后预防效果:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):475. doi: 10.1186/s13063-020-04446-4.
3
ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.羟氯喹用于 COVID-19 传染病的化学预防(PROLIFIC)以预防一线医护人员感染 COVID-19:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jul 2;21(1):604. doi: 10.1186/s13063-020-04543-4.
4
Laboratory surveillance for SARS-CoV-2 in India: Performance of testing & descriptive epidemiology of detected COVID-19, January 22 - April 30, 2020.印度对 SARS-CoV-2 的实验室监测:2020 年 1 月 22 日至 4 月 30 日检测的表现和新冠肺炎的描述性流行病学。
Indian J Med Res. 2020 May;151(5):424-437. doi: 10.4103/ijmr.IJMR_1896_20.
5
Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.羟氯喹预防 SARS-CoV-2 感染和妊娠期 COVID-19 疾病严重程度的疗效和安全性(COVID-Preg):一项随机安慰剂对照试验研究方案的结构化总结。
Trials. 2020 Jul 2;21(1):607. doi: 10.1186/s13063-020-04557-y.
6
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
7
Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?为什么用羟氯喹进行暴露前预防是一种安全且合理的针对 SARS-CoV-2 感染的方法?
J Glob Antimicrob Resist. 2020 Sep;22:864-865. doi: 10.1016/j.jgar.2020.07.022. Epub 2020 Aug 7.
8
Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.在医院环境中评估羟氯喹化学预防 SARS-CoV2 感染在医护人员中的疗效和安全性的对照、双盲、随机试验:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):472. doi: 10.1186/s13063-020-04400-4.
9
Characteristics, Treatment Outcomes and Role of Hydroxychloroquine among 522 COVID-19 hospitalized patients in Jaipur City: An Epidemio-Clinical Study.斋浦尔市522例COVID-19住院患者的羟氯喹特性、治疗结果及作用:一项流行病学临床研究
J Assoc Physicians India. 2020 Jun;68(6):13-19.
10
Hydroxychloroquine for prophylaxis in COVID-19: Need to revisit dosing regimen.羟氯喹用于COVID-19预防:需重新审视给药方案。
Indian J Med Res. 2020;152(1 & 2):130-132. doi: 10.4103/ijmr.IJMR_3077_20.